GlaxoSmithKline_NN
163_CD
Financial_NN
information_NOMZ
under_IN
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
Background_NN
Financial_NN
instruments_NOMZ
:_:
Financial_NN
instruments_NOMZ
in_PIN
the_DT
comparative_JJ
periods_NN
to_TO
be_VB [PASS]
presented_VBN
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
i._FW
e._FW
2004_CD
The_DT
IFRS_NN
project_NN
and_CC
2003_CD
are_VPRT [PASS]
recorded_VBN
on_PIN
the_DT
existing_VBG
UK_NN
GAAP_NN
basis_NN
,_,
rather_CONJ
In_PIN
June_NN
2002_CD
,_,
the_DT
Council_NN
of_PIN
the_DT
European_NN
Union_NN
adopted_VBD
a_DT
than_PIN
in_PIN
accordance_NN
with_PIN
IAS_NN
32_CD
Financial_NN
Instruments_NOMZ
:_:
Regulation_NOMZ
requiring_VBG [SUAV] [WZPRES]
listed_VBN
companies_NN
in_PIN
its_PIT
Member_NN
States_NN
to_PIN
Disclosure_NN
and_PHC
Presentation_NOMZ
and_PHC
IAS_NN
39_CD
Financial_NN
Instruments_NOMZ
:_:
prepare_VB
their_TPP3
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
accordance_NN
Recognition_NOMZ
and_PHC
Measurement_NOMZ
see_VPRT [PRIV]
below_PLACE
._.
with_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
from_PIN
2005_CD
._.
The_DT
first_JJ
GlaxoSmithKline_NN
Annual_JJ
Report_NN
prepared_VBN
under_IN
IFRS_NN
The_NN
IFRS_NN
financial_JJ
information_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
on_PIN
the_DT
basis_NN
will_PRMD
be_VB
that_DEMO
for_PIN
the_DT
year_NN
ending_VBG [WZPRES]
31st_CD
December_NN
2005_CD
._.
The_DT
first_JJ
of_PIN
taking_VBG
these_DEMO
exemptions_NOMZ
._.
financial_JJ
results_NN
announcement_NOMZ
prepared_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
IFRS_NN
will_PRMD
be_VB
that_DEMO
for_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2005_CD
._.
Financial_NN
instruments_NOMZ
GlaxoSmithKline_NN
intends_VPRT [SUAV]
to_TO
adopt_VB
IAS_NN
39_CD
in_PIN
full_JJ
._.
However_CONJ
,_,
one_CD
The_DT
Groups_NN
project_NN
to_TO
convert_VB
its_PIT
financial_JJ
reporting_GER
from_PIN
UK_NN
of_PIN
the_DT
exemptions_NOMZ
available_JJ
under_IN
IFRS_NN
1_CD
relaxes_VPRT
the_DT
requirement_NOMZ
GAAP_NN
to_PIN
IFRS_NN
has_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
completed_VBN
,_,
subject_JJ
to_PIN
any_QUAN
changes_NN
for_PIN
comparative_JJ
information_NOMZ
presented_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
in_PIN
standard_JJ
and_CC
pronouncements_NOMZ
._.
A_DT
training_GER
program_NN
has_VPRT
to_TO
comply_VB
with_PIN
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
._.
GlaxoSmithKline_NN
intends_VPRT [SUAV]
to_TO
been_VBN [PASS]
rolled_VBN
out_PIN
to_PIN
all_QUAN
finance_NN
staff_NN
worldwide_NN
and_CC
the_DT
adjusted_VBN
take_VPRT
advantage_NN
of_PIN
this_DEMO
exemption_NOMZ
,_,
and_ANDC
so_RB
,_,
in_PIN
2003_CD
and_CC
2004_CD
,_,
historical_JJ
data_NN
,_,
which_WDT [SERE]
will_PRMD
provide_VB
the_DT
comparative_JJ
information_NOMZ
financial_JJ
instruments_NOMZ
will_PRMD
be_VB [PASS]
accounted_VBN
for_PIN
and_CC
presented_VBN
on_PIN
a_DT
under_IN
IFRS_NN
in_PIN
2005_CD
,_,
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
._.
The_DT
unaudited_JJ
consolidated_JJ
results_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
On_PIN
1st_CD
January_NN
2005_CD
there_EX
was_VBD
an_DT
adjustment_NOMZ
to_PIN
the_DT
opening_GER
converted_VBD
from_PIN
the_DT
current_JJ
UK_NN
GAAP_NN
basis_NN
onto_PIN
an_DT
IFRS_NN
basis_NN
balance_NN
sheet_NN
to_TO
reect_VB
the_DT
movements_NOMZ
from_PIN
the_DT
UK_NN
GAAP_NN
for_PIN
2003_CD
and_CC
2004_CD
are_VPRT [PASS]
presented_VBN
on_PIN
pages_NN
170_CD
to_PIN
173_CD
._.
As_IN
2003_CD
carrying_VBG
values_NN
to_PIN
the_DT
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
values_NN
,_,
which_WDT [SERE]
for_PIN
many_QUAN
will_PRMD
be_VB [BEMA]
the_DT
earliest_JJ
year_NN
for_PIN
which_WDT [PIRE]
full_JJ
IFRS_NN
financial_JJ
statements_NOMZ
financial_JJ
instruments_NOMZ
will_PRMD
be_VB [BEMA]
fair_JJ
value_NN
._.
will_PRMD
be_VB [PASS]
presented_VBN
in_PIN
the_DT
Annual_JJ
Report_NN
2005_CD
,_,
the_DT
transition_NOMZ
date_NN
to_PIN
IFRS_NN
for_PIN
GlaxoSmithKline_NN
is_VPRT [BEMA]
1st_CD
January_NN
2003_CD
._.
Normally_RB
The_DT
financial_JJ
instruments_NOMZ
concerned_VBN [WZPAST]
are_VPRT
:_:
accounting_GER
changes_NN
of_PIN
this_DEMO
nature_NN
would_PRMD
require_VB [SUAV] [THATD]
full_JJ
retrospective_NN
Held_VBN [PRIV] [WZPAST]
at_PIN
fair_JJ
value_NN
under_IN
IFRS_NN
with_PIN
movements_NOMZ
recorded_VBN [WZPAST]
in_PIN
application_NOMZ
,_,
but_CC
under_IN
the_DT
IFRS_NN
transitional_JJ
rules_NN
,_,
certain_JJ
equity_NOMZ
:_:
adjustments_NOMZ
only_DWNT
have_VPRT
to_TO
be_VB [PASS]
applied_VBN
with_PIN
effect_NN
from_PIN
the_DT
Equity_NOMZ
investments_NOMZ
transition_NOMZ
date_NN
of_PIN
1st_CD
January_NN
2003_CD
._.
Liquid_NN
investments_NOMZ
Derivatives_NN
classied_VBD
as_IN
cash_NN
ow_NN
hedging_VBG [WZPRES]
instruments_NOMZ
Basis_NN
of_PIN
preparation_NOMZ
of_PIN
data_NN
The_DT
IFRS_NN
financial_JJ
information_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
on_PIN
the_DT
basis_NN
Held_VBN [PRIV] [WZPAST]
at_PIN
fair_JJ
value_NN
under_IN
IFRS_NN
with_PIN
movements_NOMZ
recorded_VBN [WZPAST]
in_PIN
of_PIN
all_QUAN
IFRS_NN
and_CC
Standing_VBG
Interpretations_NOMZ
Committee_NN
SIC_NN
and_CC
the_DT
income_NN
statement_NOMZ
:_:
International_NN
Financial_NN
Reporting_GER
Interpretations_NOMZ
Committee_NN
IFRIC_NN
Equity_NOMZ
collar_NN
linked_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
investment_NOMZ
in_PIN
Quest_NN
interpretations_NOMZ
issued_VBN [WZPAST]
by_PIN
the_DT
IASB_NN
effective_JJ
for_PIN
2005_CD
reporting_GER
._.
Put_VB
and_PHC
call_VB
options_NOMZ
linked_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
strategic_JJ
GlaxoSmithKline_NN
has_VPRT [PEAS]
chosen_VBN
to_TO
adopt_VB
the_DT
IASBs_NN
amendments_NOMZ
to_PIN
alliance_NN
with_PIN
Theravance_NN
Inc._NN
._.
IAS_NN
19_CD
,_,
Employee_NN
Benets_NN
,_,
early_TIME
._.
This_DEMP
permits_VPRT
actuarial_JJ
gains_NN
and_CC
Other_JJ
derivatives_NN
not_XX0
classied_VBD
as_IN
hedging_VBG
instruments_NOMZ
,_,
losses_NN
,_,
differences_NN
between_PIN
the_DT
expected_VBN [PRIV]
and_CC
actual_JJ
returns_NN
and_CC
including_VBG
embedded_VBN
derivatives_NN
the_DT
effect_NN
of_PIN
changes_NN
in_PIN
actuarial_JJ
assumptions_NOMZ
to_TO
be_VB [PASS]
recognized_VBN [PRIV] [THATD]
Derivatives_NN
classied_VBD
as_IN
fair_JJ
value_NN
hedges_NN
together_RB
with_PIN
in_PIN
the_DT
Statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
._.
the_DT
hedged_JJ
element_NOMZ
of_PIN
the_DT
relevant_JJ
asset_NN
or_CC
liability_NOMZ
The_DT
financial_JJ
information_NOMZ
presented_VBN
under_IN
IFRS_NN
is_VPRT [BEMA]
unaudited_PRED
._.
Presentation_NOMZ
differences_NN
only_DWNT
:_:
Non-equity_JJ
minority_NOMZ
interests_NN
repaid_VBN [WZPAST]
during_PIN
2004_CD
._.
IFRS_NN
1_CD
exemptions_NOMZ
IFRS_VPRT
1_CD
,_,
First-Time_NN
Adoption_NOMZ
of_PIN
International_NN
Financial_NN
Reporting_GER
If_COND
the_DT
IAS_NN
39_CD
valuation_NOMZ
rules_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
in_PIN
2004_CD
there_EX
Standards_NN
,_,
permits_VPRT
those_DEMO
companies_NN
adopting_VBG [WZPRES]
IFRS_NN
for_PIN
the_DT
first_JJ
would_PRMD
have_VB [PEAS]
been_VBN [BEMA]
a_DT
charge_NN
to_PIN
profit_NN
before_IN
tax_NN
,_,
the_DT
largest_JJ
time_NN
to_TO
take_VB
some_QUAN
exemptions_NOMZ
from_PIN
the_DT
full_JJ
requirements_NOMZ
of_PIN
IFRS_NN
elements_NOMZ
of_PIN
which_WDT [PIRE]
arise_VPRT
from_PIN
the_DT
Quest_NN
collar_NN
42_CD
million_CD
:_:
in_PIN
the_DT
transition_NOMZ
period_NN
._.
GlaxoSmithKline_NN
intends_VPRT [SUAV]
to_TO
take_VB
the_DT
2003_CD
42_CD
million_CD
and_CC
the_DT
Theravance_NN
put_VBD
and_PHC
call_VB
options_NOMZ
following_VBG [WZPRES]
key_JJ
exemptions_NOMZ
:_:
53_CD
million_CD
:_:
2003_CD
nil_NN
._.
Valuations_NOMZ
are_VPRT [BEMA]
inherently_RB
unpredictable_PRED
and_CC
changes_NN
in_PIN
the_DT
fair_JJ
values_NN
of_PIN
financial_JJ
instruments_NOMZ
could_POMD
Business_NOMZ
combinations_NOMZ
:_:
Business_NOMZ
combinations_NOMZ
prior_RB
to_PIN
the_DT
have_VPRT
a_DT
material_NN
impact_NN
on_PIN
the_DT
future_JJ
results_NN
and_CC
financial_JJ
transition_NOMZ
date_NN
1st_CD
January_NN
2003_CD
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
restated_VBN
position_NOMZ
of_PIN
GlaxoSmithKline_NN
._.
onto_PIN
an_DT
IFRS_NN
basis_NN
Employee_NN
benets_NN
:_:
All_QUAN
cumulative_JJ
actuarial_JJ
gains_NN
and_PHC
losses_NN
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
equity_NOMZ
at_PIN
the_DT
transition_NOMZ
date_NN
Share-based_JJ
payments_NOMZ
:_:
IFRS_NN
2_CD
,_,
Share-based_JJ
Payment_NOMZ
,_,
applies_VPRT
to_PIN
equity_NOMZ
instruments_NOMZ
,_,
such_JJ
as_IN
share_NN
options_NOMZ
granted_VBN [SUAV]
since_OSUB
7th_JJ
November_NN
2002_CD
,_,
but_CC
GlaxoSmithKline_NN
has_VPRT [PEAS]
elected_VBN
to_TO
adopt_VB
full_JJ
retrospective_NN
application_NOMZ
of_PIN
the_DT
standard_JJ
164_CD
GlaxoSmithKline_NN
Financial_NN
information_NOMZ
under_IN
IFRS_NN
IFRS_NN
accounting_GER
policies_NN
Foreign_JJ
currency_NN
transactions_NOMZ
Foreign_JJ
currency_NN
transactions_NOMZ
by_PIN
Group_NN
companies_NN
are_VPRT [PASS]
booked_VBN
The_DT
following_JJ
IFRS_NN
accounting_GER
policies_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
applied_VBN
in_PIN
local_JJ
currency_NN
at_PIN
the_DT
exchange_NN
rate_NN
ruling_NN
on_PIN
the_DT
date_NN
of_PIN
by_PIN
GlaxoSmithKline_NN
plc_NN
in_PIN
its_PIT
consolidated_JJ
financial_JJ
statements_NOMZ
for_PIN
f_SYM
transaction_NOMZ
._.
Foreign_JJ
currency_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
retranslated_VBN
2005_CD
._.
into_PIN
local_JJ
currency_NN
at_PIN
rates_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Exchange_NN
differences_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Consolidation_NOMZ
The_DT
consolidated_JJ
Financial_NN
statements_NOMZ
include_VPRT
:_:
Revenue_NN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
,_,
and_ANDC
the_DT
results_NN
and_PHC
cash_NN
ows_NN
,_,
Revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
when_RB
goods_NN
or_CC
of_PIN
the_DT
company_NN
and_CC
its_PIT
subsidiaries_NN
,_,
including_VBG
ESOP_NN
Trusts_NN
:_:
services_NN
are_VPRT [PASS]
supplied_VBN
or_CC
made_VBN
available_JJ
to_PIN
external_JJ
customers_NN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
assets_NN
and_PHC
results_NN
of_PIN
joint_JJ
against_PIN
orders_NN
received_VBN
and_ANDC
when_RB
title_NN
and_PHC
risk_NN
of_PIN
loss_NN
passes_VPRT
to_PIN
ventures_NN
and_PHC
associates_NN
._.
Turnover_NN
represents_VPRT
net_JJ
invoice_NN
value_NN
after_IN
the_DT
deduction_NOMZ
of_PIN
discounts_NN
and_PHC
allowances_NN
given_VBN
and_CC
accruals_NN
for_PIN
The_DT
Financial_NN
statements_NOMZ
of_PIN
undertakings_GER
consolidated_VBN [WZPAST]
are_VPRT [PASS]
made_VBN
up_RP
estimated_VBN [PRIV]
future_JJ
rebates_NN
and_PHC
returns_NN
._.
The_DT
methodology_NN
and_CC
to_PIN
31st_CD
December_NN
._.
assumptions_NOMZ
used_VBD
to_TO
estimate_VB [PRIV]
rebates_NN
and_PHC
returns_NN
are_VPRT [BEMA]
monitored_JJ
Entities_NOMZ
over_IN
which_WDT
the_DT
Group_NN
has_VPRT
the_DT
ability_NOMZ
to_TO
exercise_VB
control_NN
are_VPRT
and_PHC
adjusted_VBN
regularly_RB
in_PIN
the_DT
light_NN
of_PIN
contractual_JJ
and_PHC
historical_JJ
accounted_VBD
for_PIN
as_IN
subsidiaries_NN
:_:
where_RB
the_DT
Group_NN
has_VPRT
the_DT
ability_NOMZ
to_PIN
information_NOMZ
and_CC
past_JJ
experience_NN
._.
Turnover_NN
also_RB
includes_VPRT
coexercise_NN
joint_JJ
control_NN
,_,
they_TPP3
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
joint_JJ
ventures_NN
,_,
and_ANDC
promotion_NOMZ
income_NN
where_RB
the_DT
Group_NN
records_NN
its_PIT
share_NN
of_PIN
the_DT
where_RB
the_DT
Group_NN
has_VPRT
the_DT
ability_NOMZ
to_TO
exercise_VB
significant_JJ
inuence_NN
,_,
revenue_NN
but_CC
no_SYNE
related_JJ
cost_NN
of_PIN
sales_NN
._.
Value_NN
added_VBD [PUBV]
tax_NN
and_CC
other_JJ
they_TPP3
are_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
associates_NN
._.
sales_NN
taxes_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
revenue_NN
._.
Interests_NN
acquired_VBN [WZPAST]
in_PIN
entities_NOMZ
are_VPRT [PASS]
consolidated_VBN
from_PIN
the_DT
effective_JJ
Expenditure_NN
date_NN
of_PIN
acquisition_NOMZ
and_PHC
interests_NN
sold_VBN [WZPAST]
are_VPRT [PASS]
consolidated_VBN
up_RP
to_PIN
the_DT
Expenditure_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
respect_NN
of_PIN
goods_NN
and_PHC
services_NN
received_VBN
date_NN
of_PIN
disposal_NN
._.
when_RB
supplied_VBN
in_PIN
accordance_NN
with_PIN
contractual_JJ
terms_NN
._.
Provision_NN
is_VPRT
Transactions_NOMZ
and_PHC
balances_NN
between_PIN
subsidiaries_NN
are_VPRT [PASS]
eliminated_VBN
:_:
made_VBN
when_RB
an_DT
obligation_NOMZ
exists_VPRT
for_PIN
a_DT
future_JJ
liability_NOMZ
in_PIN
respect_NN
of_PIN
no_SYNE
profit_NN
is_VPRT [PASS]
taken_VBN
on_PIN
sales_NN
between_PIN
subsidiaries_NN
or_CC
on_PIN
sales_NN
to_PIN
joint_JJ
a_DT
past_JJ
event_NN
and_ANDC
where_RB
the_DT
amount_NN
of_PIN
the_DT
obligation_NOMZ
can_POMD
be_VB
ventures_NN
and_PHC
associates_NN
until_IN
the_DT
products_NN
are_VPRT [PASS]
sold_VBN
to_PIN
customers_NN
reliably_RB
estimated_VBN [PRIV]
._.
Advertising_GER
and_PHC
promotion_NOMZ
expenditure_NN
is_VPRT
outside_PLACE
the_DT
Group_NN
._.
Deferred_JJ
tax_NN
relief_NN
on_PIN
unrealised_JJ
intra-Group_JJ
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
as_IN
incurred_VBN
._.
Shipment_NOMZ
costs_NN
on_PIN
profit_NN
is_VPRT [PASS]
accounted_VBN
for_PIN
only_DWNT
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [PASS]
considered_VBN [PRIV]
intercompany_NN
transfers_NN
are_VPRT [PASS]
charged_VBN
to_PIN
cost_NN
of_PIN
sales_NN
:_:
distribution_NOMZ
recoverable_JJ
._.
costs_NN
on_PIN
sales_NN
to_PIN
customers_NN
are_VPRT [PASS]
included_VBN
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenditure_NN
._.
Restructuring_GER
costs_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
interests_NN
in_PIN
subsidiaries_NN
,_,
joint_JJ
respect_NN
of_PIN
the_DT
direct_JJ
expenditures_NN
of_PIN
a_DT
business_NOMZ
reorganisation_NOMZ
ventures_NN
and_PHC
associates_NN
,_,
representing_VBG [PRESP]
the_DT
excess_NN
of_PIN
the_DT
purchase_NN
where_RB
the_DT
plans_NN
are_VPRT [SPAU] [PASS]
sufciently_RB
detailed_VBN
and_CC
well_RB
advanced_VBD
,_,
and_ANDC
consideration_NOMZ
over_IN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
fair_JJ
values_NN
of_PIN
the_DT
where_RB
appropriate_JJ
communication_NOMZ
to_PIN
those_DEMP
affected_VBN
has_VPRT [PEAS]
been_VBN [BEMA]
identiable_JJ
assets_NN
,_,
liabilities_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
acquired_VBN
,_,
undertaken_VBN [PASTP]
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
is_VPRT [PASS]
capitalized_VBN
as_IN
a_DT
separate_JJ
item_NN
in_PIN
the_DT
case_NN
of_PIN
subsidiaries_NN
and_CC
as_IN
part_NN
of_PIN
the_DT
cost_NN
of_PIN
investment_NOMZ
in_PIN
the_DT
case_NN
of_PIN
joint_JJ
ventures_NN
and_PHC
Research_NN
and_PHC
development_NOMZ
associates_NN
._.
Goodwill_NN
is_VPRT [PASS]
denominated_VBN
in_PIN
the_DT
currency_NN
of_PIN
the_DT
Research_NN
and_PHC
development_NOMZ
expenditure_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
operation_NOMZ
acquired_VBN
._.
In_PIN
the_DT
case_NN
of_PIN
acquisitions_NOMZ
prior_RB
to_PIN
1998_CD
,_,
statement_NOMZ
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
._.
Development_NOMZ
goodwill_NN
was_VBD [PASS]
written_VBN [PUBV]
off_PIN
directly_RB
to_PIN
equity_NOMZ
:_:
on_PIN
a_DT
subsequent_JJ
expenditure_NN
is_VPRT [PASS]
capitalized_VBN
when_RB
the_DT
criteria_NN
for_PIN
recognizing_VBG [PRIV]
an_DT
asset_NN
disposal_NN
of_PIN
assets_NN
from_PIN
such_JJ
acquisitions_NOMZ
,_,
any_QUAN
related_JJ
goodwill_NN
are_VPRT [PASS]
met_VBN
,_,
usually_RB
at_PIN
the_DT
point_NN
of_PIN
regulatory_JJ
ling_NN
in_PIN
a_DT
major_JJ
market_NN
._.
remains_VPRT
in_PIN
equity_NOMZ
and_CC
is_VPRT [PASS]
not_XX0
charged_VBN
to_PIN
the_DT
consolidated_JJ
income_NN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
used_VBN [WZPAST]
for_PIN
research_NN
and_PHC
development_NOMZ
statement_NOMZ
._.
is_VPRT [PASS]
depreciated_VBN
in_PIN
accordance_NN
with_PIN
the_DT
Groups_NN
policy_NN
._.
The_DT
results_NN
and_PHC
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
are_VPRT [PASS]
incorporated_VBN
into_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
using_VBG [WZPRES]
Environmental_JJ
expenditure_NN
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
._.
Environmental_NN
expenditure_NN
related_VBN
to_TO
existing_VBG
conditions_NOMZ
resulting_VBG [WZPRES]
from_PIN
past_JJ
or_CC
current_JJ
operations_NOMZ
and_CC
from_PIN
which_WDT [PIRE]
no_SYNE
current_JJ
or_CC
Assets_NN
and_PHC
liabilities_NOMZ
of_PIN
overseas_PLACE
subsidiaries_NN
,_,
associates_NN
and_CC
joint_JJ
future_NN
benefit_NN
is_VPRT [BEMA]
discernible_PRED
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
ventures_NN
including_VBG [WZPRES]
related_JJ
goodwill_NN
,_,
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
at_PIN
The_DT
Group_NN
recognizes_VPRT [PRIV]
its_PIT
liability_NOMZ
on_PIN
a_DT
site-by-site_JJ
basis_NN
when_RB
it_PIT
can_POMD
rates_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
results_NN
and_CC
be_VB [SPAU] [PASS]
reliably_RB
estimated_VBN [PRIV]
._.
This_DEMO
liability_NOMZ
includes_VPRT
the_DT
Groups_NN
portion_NOMZ
of_PIN
cash_NN
ows_NN
of_PIN
overseas_PLACE
subsidiaries_NN
,_,
associates_NN
and_CC
joint_JJ
ventures_NN
the_DT
total_JJ
costs_NN
and_CC
also_RB
a_DT
portion_NOMZ
of_PIN
other_JJ
potentially_RB
responsible_JJ
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
using_VBG [WZPRES]
average_JJ
rates_NN
of_PIN
exchange_NN
._.
parties_NN
costs_NN
when_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
they_TPP3
will_PRMD
not_XX0
be_VB [BEMA]
able_PRED
to_PIN
Exchange_NN
adjustments_NOMZ
arising_VBG [WZPRES]
when_RB
the_DT
opening_GER
net_JJ
assets_NN
and_CC
satisfy_VB
their_TPP3
respective_JJ
shares_NN
of_PIN
the_DT
clean-up_JJ
obligation_NOMZ
._.
Recoveries_NN
the_DT
profits_NN
for_PIN
the_DT
year_NN
retained_VBN [WZPAST]
by_PIN
overseas_PLACE
subsidiaries_NN
,_,
associates_NN
of_PIN
reimbursements_NOMZ
are_VPRT [PASS]
recorded_VBN
as_IN
assets_NN
when_RB
virtually_RB
certain_JJ
._.
and_ANDC
joint_JJ
ventures_NN
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
,_,
less_JJ
exchange_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
related_VBN
foreign_JJ
currency_NN
borrowings_GER
which_WDT [WHSUB]
hedge_VPRT
the_DT
Groups_NN
net_JJ
investment_NOMZ
in_PIN
these_DEMO
operations_NOMZ
,_,
are_VPRT [PASS]
taken_VBN
to_PIN
a_DT
separate_JJ
component_NN
of_PIN
equity_NOMZ
._.
When_RB
translating_VBG
into_PIN
sterling_GER
the_DT
assets_NN
,_,
liabilities_NOMZ
,_,
results_NN
and_PHC
cash_NN
ows_NN
of_PIN
overseas_PLACE
subsidiaries_NN
,_,
associates_NN
and_CC
joint_JJ
ventures_NN
which_WDT [WHSUB]
are_VPRT [PASS]
reported_VBN [PUBV]
in_PIN
currencies_NN
of_PIN
hyper-inationary_JJ
economies_NN
,_,
adjustments_NOMZ
are_VPRT [PASS]
made_VBN
to_TO
reect_VB
current_JJ
price_NN
levels_NN
._.
Any_QUAN
loss_NN
on_PIN
net_JJ
monetary_JJ
assets_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
consolidated_JJ
income_NN
statement_NOMZ
._.
Financial_NN
information_NOMZ
under_IN
IFRS_NN
GlaxoSmithKline_NN
165_CD
IFRS_NN
accounting_GER
policies_NN
continued_VBD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
PP&E_NN
is_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
cost_NN
of_PIN
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
purchase_NN
or_CC
construction_NOMZ
less_RB
provisions_NN
for_PIN
depreciation_NOMZ
and_CC
The_DT
costs_NN
of_PIN
providing_VBG
pensions_NN
under_IN
dened_VBN
benefit_NN
schemes_NN
are_VPRT
impairment_NOMZ
._.
Financing_GER
costs_NN
are_VPRT [PASS]
not_XX0
capitalized_VBN
._.
calculated_VBN [PRIV]
using_VBG
the_DT
projected_VBN
unit_NN
credit_NN
method_NN
and_PHC
spread_NN
over_IN
the_DT
period_NN
during_PIN
which_WDT [PIRE]
benefit_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
derived_VBN
from_PIN
the_DT
Depreciation_NOMZ
is_VPRT [PASS]
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
of_PIN
PP&E_NN
,_,
excluding_VBG
employees_NN
services_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
qualied_JJ
freehold_JJ
land_NN
,_,
using_VBG [PRESP]
the_DT
straight-line_JJ
basis_NN
over_IN
its_PIT
expected_VBN [PRIV]
useful_JJ
actuaries_NN
._.
Pension_NN
obligations_NOMZ
are_VPRT [PASS]
measured_VBN
as_IN
the_DT
present_JJ
value_NN
life_NN
._.
The_DT
normal_JJ
expected_VBN [PRIV]
useful_JJ
lives_NN
of_PIN
the_DT
major_JJ
categories_NN
of_PIN
of_PIN
estimated_JJ
future_JJ
cash_NN
ows_VPRT
discounted_VBN
at_PIN
rates_NN
reecting_VBG [WZPRES]
the_DT
PP&E_NN
are_VPRT [PASS]
reviewed_VBN
annually_RB
and_CC
are_VPRT
:_:
yields_NN
of_PIN
high_JJ
quality_NOMZ
corporate_JJ
bonds_NN
._.
Pension_NN
scheme_NN
assets_NN
are_VPRT
Freehold_NN
buildings_GER
20_CD
to_PIN
50_CD
years_NN
measured_VBN [WZPAST]
at_PIN
fair_JJ
value_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Actuarial_JJ
gains_NN
Leasehold_NN
land_NN
and_PHC
Lease_NN
term_NN
or_CC
20_CD
to_PIN
50_CD
years_NN
and_PHC
losses_NN
,_,
differences_NN
between_PIN
the_DT
expected_VBN [PRIV]
and_CC
actual_JJ
returns_NN
,_,
buildings_GER
and_CC
the_DT
effect_NN
of_PIN
changes_NN
in_PIN
actuarial_JJ
assumptions_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
Plant_NN
and_PHC
machinery_NN
10_CD
to_PIN
20_CD
years_NN
in_PIN
the_DT
Statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
in_PIN
the_DT
Fixtures_NN
and_PHC
equipment_NOMZ
3_CD
to_PIN
10_CD
years_NN
year_NN
they_TPP3
arise_VPRT
._.
The_DT
Groups_NN
contributions_NOMZ
to_PIN
dened_JJ
contribution_NOMZ
plans_NN
are_VPRT [BEMA]
On_PIN
disposal_NN
of_PIN
PP&E_NN
,_,
the_DT
cost_NN
and_CC
related_JJ
accumulated_VBN
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
as_IN
incurred_VBN
._.
depreciation_NOMZ
and_PHC
impairments_NOMZ
are_VPRT [PASS]
removed_VBN
from_PIN
the_DT
financial_JJ
statements_NOMZ
and_CC
the_DT
net_JJ
amount_NN
,_,
less_JJ
any_QUAN
proceeds_NN
,_,
is_VPRT [PASS]
taken_VBN
to_PIN
The_DT
costs_NN
of_PIN
other_JJ
post-employment_NOMZ
liabilities_NOMZ
are_VPRT [PASS]
calculated_VBN [PRIV]
in_PIN
a_DT
the_DT
income_NN
statement_NOMZ
._.
similar_JJ
way_NN
to_TO
dened_VBN
benefit_NN
pension_NN
schemes_NN
and_PHC
spread_NN
over_IN
the_DT
period_NN
during_PIN
which_WDT [PIRE]
benefit_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
derived_VBN
from_PIN
Leases_NN
the_DT
employees_NN
services_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
qualied_JJ
Leasing_GER
agreements_NOMZ
which_WDT [WHSUB]
transfer_VPRT
to_PIN
the_DT
Group_NN
substantially_RB
actuaries_NN
._.
all_QUAN
the_DT
benets_NN
and_PHC
risks_NN
of_PIN
ownership_NN
of_PIN
an_DT
asset_NN
are_VPRT [PASS]
treated_VBN
as_IN
finance_NN
leases_NN
,_,
as_IN
if_COND
the_DT
asset_NN
had_VBD [PEAS]
been_VBN [PASS]
purchased_VBN
outright_RB
._.
The_DT
Legal_NN
and_CC
other_JJ
disputes_NN
assets_NN
are_VPRT [PASS]
included_VBN
in_PIN
PP&E_NN
or_CC
computer_NN
software_NN
and_CC
the_DT
capital_NN
Provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
anticipated_JJ
settlement_NOMZ
costs_NN
where_RB
a_DT
elements_NOMZ
of_PIN
the_DT
leasing_GER
commitments_NOMZ
are_VPRT [PASS]
shown_VBN [PRIV]
as_IN
obligations_NOMZ
reasonable_JJ
estimate_NN
can_POMD
be_VB [PASS]
made_VBN
of_PIN
the_DT
likely_JJ
outcome_NN
of_PIN
legal_JJ
or_CC
under_IN
finance_NN
leases_NN
._.
Assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
are_VPRT [BEMA]
other_JJ
disputes_NN
against_PIN
the_DT
Group_NN
._.
In_CONJ
addition_NULL
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
depreciated_VBN
on_PIN
a_DT
basis_NN
consistent_JJ
with_PIN
similar_JJ
owned_VBN
assets_NN
or_CC
legal_JJ
or_CC
other_JJ
expenses_NN
arising_VBG [WZPRES]
from_PIN
claims_NN
received_VBN
or_CC
other_JJ
the_DT
lease_NN
term_NN
if_COND
shorter_JJ
._.
The_DT
interest_NN
element_NOMZ
of_PIN
the_DT
lease_NN
rental_JJ
disputes_NN
._.
In_PIN
respect_NN
of_PIN
product_NN
liability_NOMZ
claims_NN
related_VBN [WZPAST]
to_PIN
products_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
All_QUAN
other_JJ
leases_NN
are_VPRT
operating_VBG
where_RB
there_EX
is_VPRT
sufficient_JJ
history_NN
of_PIN
claims_NN
made_VBN
and_CC
settlements_NOMZ
,_,
an_DT
leases_NN
and_CC
the_DT
annual_JJ
rentals_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
incurred_VBN
but_CC
not_XX0
reported_VBD [PUBV]
IBNR_NN
actuarial_JJ
technique_NN
is_VPRT [PASS]
used_VBN
to_PIN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
lease_NN
term_NN
._.
determine_VB [SUAV] [PRIV]
a_DT
reasonable_JJ
estimate_NN
of_PIN
the_DT
Groups_NN
exposure_NN
to_PIN
unasserted_JJ
claims_NN
for_PIN
those_DEMO
products_NN
and_CC
a_DT
provision_NN
is_VPRT [PASS]
made_VBN
on_PIN
Goodwill_NN
that_DEMP
basis_NN
._.
No_SYNE
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
other_JJ
unasserted_JJ
claims_NN
or_CC
Goodwill_NN
is_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
impairments_NOMZ
._.
Goodwill_NN
is_VPRT [PASS]
deemed_VBN [PRIV]
to_PIN
where_RB
an_DT
obligation_NOMZ
exists_VPRT
under_IN
a_DT
dispute_NN
but_CC
it_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
to_TO
have_VB
an_DT
indefinite_JJ
useful_JJ
life_NN
and_CC
is_VPRT [PASS]
tested_VBN
for_PIN
impairment_NOMZ
annually_RB
._.
Costs_NN
associated_VBN [WZPAST]
with_PIN
claims_NN
made_VBN [WZPAST]
by_PIN
the_DT
Group_NN
against_PIN
third_JJ
parties_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
Where_RB
the_DT
fair_JJ
value_NN
of_PIN
the_DT
interest_NN
acquired_VBN [WZPAST]
in_PIN
an_DT
entitys_JJ
assets_NN
,_,
statement_NOMZ
as_IN
they_TPP3
are_VPRT [PASS]
incurred_VBN
._.
liabilities_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
exceeds_VPRT
the_DT
consideration_NOMZ
paid_VBN
,_,
this_DEMO
excess_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
immediately_TIME
as_IN
a_DT
gain_NN
in_PIN
the_DT
income_NN
Employee_NN
share_NN
plans_VPRT
statement_NOMZ
._.
Incentives_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
are_VPRT [PASS]
provided_VBN
to_PIN
employees_NN
under_IN
share_NN
option_NOMZ
and_PHC
share_NN
award_NN
schemes_NN
._.
These_DEMO
options_NOMZ
and_PHC
awards_NN
are_VPRT [BEMA]
fair_PRED
valued_VBN
at_PIN
their_TPP3
grant_NN
dates_NN
and_CC
the_DT
cost_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
over_IN
the_DT
relevant_JJ
vesting_GER
periods_NN
._.
The_DT
Group_NN
provides_VPRT
finance_NN
to_PIN
ESOP_NN
Trusts_NN
to_TO
purchase_VB
company_NN
shares_NN
on_PIN
the_DT
open_JJ
market_NN
to_TO
meet_VB
the_DT
obligation_NOMZ
to_TO
provide_VB
shares_NN
when_RB
employees_NN
exercise_VPRT
their_TPP3
options_NOMZ
or_CC
awards_NN
._.
Costs_NN
of_PIN
running_VBG
the_DT
ESOP_NN
Trusts_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOP_NN
Trusts_NN
are_VPRT [PASS]
deducted_VBN
from_PIN
other_JJ
reserves_NN
and_CC
held_VBN [PRIV]
at_PIN
the_DT
value_NN
of_PIN
the_DT
proceeds_NN
receivable_NN
from_PIN
employees_NN
on_PIN
exercise_NN
._.
If_COND
there_EX
is_VPRT [PASS]
deemed_VBN [PRIV]
to_TO
be_VB [BEMA]
a_DT
permanent_JJ
impairment_NOMZ
in_PIN
value_NN
this_DEMP
is_VPRT [BYPA]
reected_VBN
by_PIN
a_DT
transfer_NN
to_TO
retained_VBN
earnings_GER
._.
166_CD
GlaxoSmithKline_NN
Financial_NN
information_NOMZ
under_IN
IFRS_NN
IFRS_NN
accounting_GER
policies_NN
continued_VBD
Inventories_NN
Inventories_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
financial_JJ
statements_NOMZ
at_PIN
the_DT
lower_JJ
Intangible_NN
xed_VBD
assets_NN
of_PIN
cost_NN
including_VBG [WZPRES]
raw_JJ
materials_NN
,_,
direct_JJ
labor_NN
,_,
other_JJ
direct_JJ
costs_NN
Intangible_JJ
assets_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
provisions_NN
for_PIN
amortisation_NOMZ
and_CC
related_JJ
production_NOMZ
overheads_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
generally_RB
determined_VBN [SUAV] [PRIV]
on_PIN
a_DT
first_JJ
in_PIN [STPR]
,_,
first_RB
out_PIN
basis_NN
._.
Licences_NN
,_,
patents_NN
,_,
know-how_NN
and_PHC
marketing_GER
rights_NN
separately_RB
acquired_VBN
or_CC
acquired_VBN
as_IN
part_NN
of_PIN
a_DT
business_NOMZ
combination_NOMZ
are_VPRT [PASS]
Taxation_NOMZ
amortised_VBD
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
from_PIN
the_DT
time_NN
they_TPP3
Deferred_VBD
tax_NN
is_VPRT [PASS]
provided_VBN
in_PIN
full_JJ
,_,
using_VBG [PRESP]
the_DT
liability_NOMZ
method_NN
,_,
on_PIN
are_VPRT [BEMA]
available_PRED
for_PIN
use_NN
._.
The_DT
estimated_VBN [PRIV]
useful_JJ
lives_NN
for_PIN
determining_VBG [SUAV] [PRIV] [THATD]
temporary_JJ
differences_NN
arising_VBG [WZPRES]
between_PIN
the_DT
tax_NN
bases_NN
of_PIN
assets_NN
the_DT
amortisation_NOMZ
charge_NN
are_VPRT [PASS]
reviewed_VBN
annually_RB
,_,
and_ANDC
take_VB
into_PIN
and_CC
liabilities_NOMZ
and_CC
their_TPP3
carrying_VBG
amounts_NN
in_PIN
the_DT
financial_JJ
account_NN
the_DT
estimated_VBN [PRIV]
time_NN
it_PIT
takes_VPRT
to_TO
bring_VB
the_DT
compounds_NN
or_CC
statements_NOMZ
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
products_NN
to_PIN
market_NN
._.
Any_QUAN
development_NOMZ
costs_VPRT
incurred_VBN
by_PIN
the_DT
Group_NN
that_TOBJ
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
future_JJ
taxable_JJ
profits_NN
will_PRMD
be_VB [BEMA]
available_PRED
and_CC
associated_VBN
with_PIN
acquired_VBN
licences_NN
,_,
patents_NN
,_,
know-how_NN
or_CC
against_PIN
which_WDT [PIRE]
the_DT
temporary_JJ
differences_NN
can_POMD
be_VB [PASS]
utilised_VBN
._.
marketing_GER
rights_NN
are_VPRT [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
the_DT
income_NN
statement_NOMZ
Deferred_JJ
tax_NN
is_VPRT [PASS]
provided_VBN
on_PIN
temporary_JJ
differences_NN
arising_VBG [WZPRES]
on_PIN
when_RB
incurred_VBN
,_,
unless_COND
the_DT
criteria_NN
for_PIN
recognition_NOMZ
of_PIN
an_DT
internally_RB
investments_NOMZ
in_PIN
subsidiaries_NN
,_,
associates_NN
and_CC
joint_JJ
ventures_NN
,_,
except_PIN
generated_VBN
intangible_JJ
asset_NN
are_VPRT [PASS]
met_VBN
._.
where_RB
the_DT
timing_NN
of_PIN
the_DT
reversal_NN
of_PIN
the_DT
temporary_JJ
difference_NN
can_POMD
Brands_NN
are_VPRT [PASS]
valued_VBN
independently_RB
as_IN
part_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
be_VB [PASS]
controlled_VBN
and_CC
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
the_DT
temporary_JJ
difference_NN
businesses_NOMZ
acquired_VBN [WZPAST]
from_PIN
third_JJ
parties_NN
where_RB
the_DT
brand_NN
has_VPRT
a_DT
will_PRMD
not_XX0
reverse_VB
in_PIN
the_DT
foreseeable_JJ
future_NN
._.
value_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
substantial_PRED
and_PHC
long-term_PRED
and_ANDC
where_RB
the_DT
brands_NN
Deferred_VBN
tax_NN
is_VPRT [PASS]
provided_VBN
using_VBG
rates_NN
of_PIN
tax_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
can_POMD
be_VB [PASS]
sold_VBN
separately_RB
from_PIN
the_DT
rest_NN
of_PIN
the_DT
businesses_NOMZ
acquired_VBN
._.
or_CC
substantively_RB
enacted_VBN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Deferred_JJ
tax_NN
Brands_NN
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
,_,
except_PIN
liabilities_NOMZ
and_PHC
assets_NN
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
where_RB
it_PIT
is_VPRT [PASS]
considered_VBN [PRIV]
that_THVC
the_DT
useful_JJ
economic_JJ
life_NN
is_VPRT [BEMA]
indefinite_PRED
._.
Prior_RB
to_PIN
1998_CD
,_,
acquired_VBN
minor_JJ
brands_NN
and_CC
similar_JJ
intangibles_NN
were_VBD [BEMA]
Derivative_PRED
f_SYM
financial_JJ
instruments_NOMZ
and_CC
hedging_VBG
activities_NOMZ
eliminated_VBN [WZPAST]
in_PIN
the_DT
Group_NN
balance_NN
sheet_NN
against_PIN
reserves_NN
in_PIN
the_DT
year_NN
Derivative_JJ
financial_JJ
instruments_NOMZ
are_VPRT [PASS]
used_VBN
to_TO
manage_VB
exposure_NN
to_PIN
of_PIN
acquisition_NOMZ
._.
market_NN
risks_NN
from_PIN
treasury_NN
operations_NOMZ
._.
The_DT
principal_JJ
derivative_NN
instruments_NOMZ
used_VBN [WZPAST]
by_PIN
GlaxoSmithKline_NN
are_VPRT [BEMA]
foreign_JJ
currency_NN
swaps_NN
,_,
The_DT
costs_NN
of_PIN
acquiring_VBG
and_PHC
developing_VBG
computer_NN
software_NN
for_PIN
interest_NN
rate_NN
swaps_NN
and_CC
forward_RB
foreign_JJ
exchange_NN
contracts_NN
._.
internal_JJ
use_NN
and_PHC
internet_NN
sites_NN
for_PIN
external_JJ
use_NN
are_VPRT [PASS]
capitalized_VBN
as_IN
The_DT
Group_NN
does_VPRT
not_XX0
hold_VB [PRIV]
or_CC
issue_VB
derivative_JJ
financial_JJ
instruments_NOMZ
intangible_JJ
xed_VBD
assets_NN
where_RB
the_DT
software_NN
or_CC
site_NN
supports_VPRT
a_DT
for_PIN
trading_GER
or_CC
speculative_JJ
purposes_NN
._.
significant_JJ
business_NOMZ
system_NN
and_CC
the_DT
expenditure_NN
leads_VPRT
to_PIN
the_DT
creation_NOMZ
of_PIN
a_DT
durable_JJ
asset_NN
._.
ERP_NN
systems_NN
software_NN
is_VPRT [PASS]
amortised_VBN
Derivative_JJ
financial_JJ
instruments_NOMZ
are_VPRT [SPAU] [PASS]
initially_TIME
recognized_VBN [PRIV]
in_PIN
the_DT
over_JJ
seven_CD
years_NN
and_CC
other_JJ
computer_NN
software_NN
over_IN
three_CD
to_TO
balance_VB
sheet_NN
at_PIN
cost_NN
and_CC
then_RB
remeasured_VBD
at_PIN
subsequent_JJ
five_CD
years_NN
._.
reporting_VBG [PUBV]
dates_NN
to_PIN
fair_JJ
value_NN
._.
Hedging_VBG
derivatives_NN
are_VPRT [PASS]
classied_VBN
on_PIN
inception_NOMZ
as_IN
fair_JJ
value_NN
hedges_NN
,_,
cash_NN
ow_NN
hedges_NN
or_CC
net_JJ
Impairment_NOMZ
of_PIN
non-current_JJ
assets_NN
investment_NOMZ
hedges_NN
._.
The_DT
carrying_VBG
values_NN
of_PIN
all_QUAN
non-current_JJ
assets_NN
are_VPRT [PASS]
reviewed_VBN
for_PIN
Changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
derivatives_NN
designated_VBN
as_IN
fair_JJ
value_NN
impairment_NOMZ
when_RB
there_EX
is_VPRT
an_DT
indication_NOMZ
that_TOBJ
the_DT
assets_NN
might_POMD
hedges_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
,_,
with_PIN
the_DT
changes_NN
be_VB [PASS]
impaired_VBN
._.
Additionally_RB
,_,
goodwill_NN
,_,
intangible_JJ
assets_NN
with_PIN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
hedged_JJ
asset_NN
or_CC
liability_NOMZ
._.
indefinite_JJ
useful_JJ
lives_NN
and_CC
intangible_JJ
assets_NN
which_WDT [WHSUB]
are_VPRT
not_XX0
yet_RB
available_PRED
for_PIN
use_NN
are_VPRT [PASS]
tested_VBN
for_PIN
impairment_NOMZ
annually_RB
._.
Any_QUAN
Changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
derivatives_NN
designated_VBN
as_IN
cash_NN
ow_NN
provision_NN
for_PIN
impairment_NOMZ
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
hedges_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
equity_NOMZ
._.
Amounts_NN
deferred_VBN [WZPAST]
in_PIN
equity_NOMZ
are_VPRT [BEMA]
in_PIN
the_DT
year_NN
concerned_VBN
._.
transferred_VBN [PASTP]
to_PIN
the_DT
income_NN
statement_NOMZ
in_PIN
line_NN
with_PIN
the_DT
hedged_VBN
forecast_NN
transaction_NOMZ
._.
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
Hedges_NN
of_PIN
net_JJ
investments_NOMZ
in_PIN
foreign_JJ
entities_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
are_VPRT [PASS]
carried_VBN
in_PIN
the_DT
in_PIN
a_DT
similar_JJ
way_NN
to_TO
cash_VB
ow_NN
hedges_NN
._.
consolidated_JJ
balance_NN
sheet_NN
at_PIN
the_DT
Groups_NN
share_NN
of_PIN
their_TPP3
net_JJ
assets_NN
at_PIN
date_NN
of_PIN
acquisition_NOMZ
and_CC
of_PIN
their_TPP3
post-acquisition_JJ
retained_VBN
profits_NN
Changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
any_QUAN
derivative_JJ
instruments_NOMZ
that_TSUB
do_VPRT [PROD]
or_CC
losses_NN
together_RB
with_PIN
any_QUAN
goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
._.
not_XX0
qualify_VB
for_PIN
hedge_JJ
accounting_GER
are_VPRT [PASS]
recognized_VBN [PRIV]
immediately_TIME
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Available-for-sale_JJ
investments_NOMZ
Available-for-sale_JJ
investments_NOMZ
are_VPRT [SPAU] [PASS]
initially_TIME
recorded_VBN
at_PIN
cost_NN
and_PHC
Debt_NN
instruments_NOMZ
then_RB
remeasured_VBD
at_PIN
subsequent_JJ
reporting_GER
dates_NN
to_PIN
fair_JJ
value_NN
._.
Unhedged_JJ
debt_NN
instruments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
amount_NN
of_PIN
net_JJ
Unrealised_JJ
gains_NN
and_PHC
losses_NN
on_PIN
available-for-sale_JJ
investments_NOMZ
are_VPRT
proceeds_NN
,_,
adjusted_VBN
to_TO
amortise_VB
the_DT
issue_NN
costs_NN
of_PIN
the_DT
debt_NN
over_IN
recognized_VBN [PRIV]
directly_RB
in_PIN
equity_NOMZ
._.
On_PIN
disposal_NN
or_CC
impairment_NOMZ
of_PIN
the_DT
its_PIT
term_NN
._.
investments_NOMZ
,_,
the_DT
gains_NN
and_PHC
losses_NN
in_PIN
equity_NOMZ
are_VPRT [PASS]
recycled_VBN
into_PIN
the_DT
income_NN
statement_NOMZ
._.
Equity_NOMZ
investments_NOMZ
are_VPRT [PASS]
recorded_VBN
in_PIN
non-current_JJ
assets_NN
unless_COND
they_TPP3
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
sold_VBN
within_PIN
one_CD
year_NN
._.
Financial_NN
information_NOMZ
under_IN
IFRS_NN
GlaxoSmithKline_NN
167_CD
IFRS_NN
adjustments_NOMZ
The_DT
adjustment_NOMZ
for_PIN
share-based_JJ
payments_NOMZ
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
reduce_VB
to_PIN
a_DT
more_EMPH
normal_JJ
level_NN
of_PIN
200-250_CD
million_CD
by_PIN
2005_CD
._.
The_DT
A_DT
summary_NN
of_PIN
the_DT
principal_JJ
differences_NN
between_PIN
UK_NN
GAAP_NN
and_CC
considerably_RB
higher_JJ
charge_NN
in_PIN
2004_CD
and_CC
2003_CD
arises_VPRT
from_PIN
two_CD
IFRS_NN
as_IN
they_TPP3
apply_VPRT
to_PIN
GlaxoSmithKline_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
and_CC
the_DT
main_JJ
factors_NN
._.
Relatively_RB
few_QUAN
share_NN
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
during_PIN
financial_JJ
effect_NN
is_VPRT [PASS]
shown_VBN [PRIV]
on_PIN
pages_NN
170_CD
to_PIN
173_CD
._.
2000_CD
when_RB
the_DT
GW_NN
SB_NN
merger_NN
was_VBD
being_VBG [PASS]
nalised_VBN
,_,
but_CC
then_RB
in_PIN
Customer_NN
allowances_NN
2001_CD
there_EX
was_VBD
a_DT
full_JJ
catch-up_NN
grant_NN
early_TIME
in_PIN
the_DT
year_NN
followed_VBD
This_DEMO
adjustment_NOMZ
is_VPRT [BEMA]
a_DT
reclassication_NOMZ
between_PIN
turnover_NN
and_CC
by_PIN
the_DT
normal_JJ
annual_JJ
grant_NN
in_PIN
November_NN
2001_CD
._.
In_CONJ
addition_NULL
,_,
the_DT
expenses_NN
with_PIN
no_SYNE
profit_NN
or_CC
cash_NN
ow_NN
effect_NN
._.
IFRS_NN
has_VPRT
no_SYNE
detailed_JJ
grants_NN
in_PIN
2001_CD
were_VBD [PASS]
made_VBN
at_PIN
an_DT
average_JJ
share_NN
price_NN
in_PIN
excess_NN
of_PIN
rules_NN
in_PIN
relation_NOMZ
to_PIN
when_RB
certain_JJ
marketing_GER
and_CC
promotional_JJ
18_CD
._.
These_DEMO
share_NN
options_NOMZ
will_PRMD
become_VB
exercisable_JJ
in_PIN
2004_CD
and_CC
expenditure_NN
should_NEMD
be_VB [PASS]
deducted_VBN
from_PIN
turnover_NN
rather_RB
than_PIN
therefore_CONJ
fall_VB
out_PIN
of_PIN
the_DT
charge_NN
in_PIN
2005_CD
,_,
when_RB
the_DT
charge_NN
will_PRMD
recorded_VBN
as_IN
an_DT
expense_NN
._.
However_CONJ
,_,
these_DEMO
rules_NN
do_EMPH
exist_VB
under_IN
US_FPP1
reect_VB
more_EMPH
current_JJ
share_NN
prices_NN
and_CC
more_EMPH
normal_JJ
grant_NN
levels_NN
._.
GAAP_NN
in_PIN
EITF_NN
01-09_CD
,_,
Accounting_GER
for_PIN
Consideration_NOMZ
Given_VBN [WZPAST]
by_PIN
a_DT
Vendor_NN
to_PIN
a_DT
Customer_NN
,_,
which_WDT [SERE]
requires_VPRT [SUAV]
most_EMPH
marketing_GER
,_,
advertising_GER
,_,
Coreg_NN
capitalization_NOMZ
and_PHC
amortisation_NOMZ
and_PHC
promotion_NOMZ
payments_NOMZ
made_VBD
to_PIN
customers_NN
to_TO
be_VB [PASS]
deducted_VBN
from_PIN
The_DT
North_PLACE
American_JJ
rights_NN
to_PIN
Coreg_NN
were_VBD [PASS]
acquired_VBN
at_PIN
the_DT
time_NN
of_PIN
turnover_NN
._.
This_DEMP
has_VPRT
the_DT
most_EMPH
significant_JJ
impact_NN
in_PIN
the_DT
Consumer_NN
the_DT
GW_NN
SB_NN
merger_NN
as_IN
partial_JJ
consideration_NOMZ
for_PIN
the_DT
required_VBN [SUAV]
disposal_NN
Healthcare_NN
business_NOMZ
where_RB
payments_NOMZ
to_PIN
large_JJ
retailers_NN
for_PIN
in-store_JJ
of_PIN
Kytril_NN
to_PIN
Roche_NN
._.
Under_IN
UK_NN
GAAP_NN
this_DEMP
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
advertising_GER
,_,
preferential_JJ
shelf-space_NN
,_,
product_NN
listings_GER
etc._FW
._.
are_VPRT [BEMA]
an_DT
exchange_NN
of_PIN
assets_NN
with_PIN
no_SYNE
value_NN
being_VBG [WZPRES] [PASS]
attributed_VBN
to_PIN
Coreg_NN
commonplace_NN
._.
IFRS_NN
,_,
however_CONJ
,_,
requires_VPRT [SUAV]
the_DT
acquired_VBN
rights_NN
to_PIN
Coreg_NN
to_TO
be_VB [PASS]
added_VBN [PUBV]
to_PIN
intangible_JJ
assets_NN
at_PIN
their_TPP3
fair_JJ
value_NN
on_PIN
GlaxoSmithKline_NN
believes_VPRT [PRIV] [THATD]
that_DEMP
this_DEMP
reects_VPRT
best_JJ
practice_NN
in_PIN
revenue_NN
the_DT
date_NN
of_PIN
acquisition_NOMZ
of_PIN
$_$
400_CD
million_CD
,_,
and_ANDC
then_RB
amortised_VBN
over_IN
recognition_NOMZ
and_ANDC
hence_CONJ
,_,
in_PIN
the_DT
absence_NN
of_PIN
detailed_JJ
guidance_NN
under_IN
their_TPP3
remaining_VBG
useful_JJ
life_NN
of_PIN
eight_CD
years_NN
._.
This_DEMO
adjustment_NOMZ
reduces_VPRT
IFRS_NN
,_,
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
to_TO
adopt_VB
a_DT
revenue_NN
recognition_NOMZ
policy_NN
under_IN
2004_CD
profit_NN
before_IN
tax_NN
by_PIN
27_CD
million_CD
2003_CD
31_CD
million_CD
and_CC
IFRS_NN
in_PIN
line_NN
with_PIN
EITF_NN
01-09_CD
._.
Therefore_CONJ
going_VBG
forward_RB
there_EX
would_PRMD
EPS_VB
by_PIN
0.3_CD
pence_NN
2003_CD
0.3_CD
pence_NN
._.
be_VB [BEMA]
no_SYNE
difference_NN
between_PIN
turnover_NN
reported_VBN [PUBV]
under_IN
IFRS_NN
and_PHC
turnover_NN
reported_VBN [PUBV]
under_IN
US_FPP1
GAAP_NN
._.
This_DEMO
adjustment_NOMZ
has_VPRT
no_SYNE
impact_NN
Other_JJ
intangible_JJ
assets_NN
amortisation_NOMZ
on_PIN
profit_NN
before_IN
tax_NN
or_CC
EPS_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
GlaxoSmithKline_NN
amortises_VPRT
intangible_JJ
assets_NN
over_IN
their_TPP3
estimated_VBN [PRIV]
expected_VBN [PRIV]
useful_JJ
lives_NN
from_PIN
acquisition_NOMZ
,_,
which_WDT [SERE]
can_POMD
Share-based_JJ
payments_NOMZ
be_VB [BEMA]
up_RB
to_PIN
a_DT
maximum_NN
of_PIN
15_CD
years_NN
._.
IFRS_NN
only_DWNT
permits_VPRT
amortisation_NOMZ
to_PIN
The_DT
present_JJ
UK_NN
GAAP_NN
approach_NN
to_PIN
share-based_JJ
payments_NOMZ
is_VPRT
to_TO
commence_VB
when_RB
the_DT
asset_NN
becomes_VPRT
available_JJ
for_PIN
use_NN
,_,
with_PIN
annual_JJ
record_NN
any_QUAN
intrinsic_JJ
loss_NN
on_PIN
grant_NN
suffered_VBN [WZPAST]
by_PIN
the_DT
company_NN
._.
This_DEMO
impairment_NOMZ
testing_GER
required_VBN [SUAV]
before_IN
this_DEMO
point_NN
._.
GlaxoSmithKline_NN
has_VPRT
means_VPRT [PRIV]
that_THVC
for_PIN
share_NN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
at_PIN
the_DT
market_NN
price_NN
,_,
there_EX
determined_VBD [SUAV] [PRIV]
that_THVC
the_DT
point_NN
at_PIN
which_WDT [PIRE]
amortisation_NOMZ
of_PIN
product-related_JJ
is_VPRT [BEMA]
no_SYNE
charge_NN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
Where_RB
shares_NN
or_CC
options_NOMZ
assets_NN
commences_NN
under_IN
IFRS_NN
will_PRMD [SPAU]
normally_RB
be_VB [BEMA]
regulatory_JJ
approval_NN
._.
are_VPRT [PASS]
granted_VBN [SUAV]
at_PIN
no_SYNE
cost_NN
to_PIN
the_DT
employee_NN
e._FW
g._FW
under_IN
long-term_JJ
The_DT
majority_NOMZ
of_PIN
GlaxoSmithKlines_NN
intangible_JJ
assets_NN
relates_VPRT
to_PIN
the_DT
incentive_NN
plans_VPRT
the_DT
income_NN
statement_NOMZ
is_VPRT [PASS]
charged_VBN
with_PIN
an_DT
amount_NN
acquisition_NOMZ
of_PIN
rights_NN
to_PIN
compounds_NN
in_PIN
development_NOMZ
and_CC
so_RB
has_VPRT
not_XX0
equal_JJ
to_PIN
the_DT
market_NN
price_NN
on_PIN
the_DT
date_NN
of_PIN
the_DT
award_NN
,_,
spread_VBN
over_IN
reached_VBN
the_DT
point_NN
at_PIN
which_WDT [PIRE]
amortisation_NOMZ
commences_NN
._.
This_DEMP
has_VPRT [PEAS]
led_VBN
the_DT
performance_NN
period_NN
usually_RB
three_CD
years_NN
._.
to_PIN
a_DT
reduction_NOMZ
in_PIN
the_DT
amortisation_NOMZ
charge_NN
in_PIN
the_DT
periods_NN
presented_VBN
,_,
IFRS_NN
2_CD
,_,
Share-based_JJ
Payment_NOMZ
,_,
and_ANDC
its_PIT
UK_NN
GAAP_NN
equivalent_JJ
FRS_NN
20_CD
,_,
which_WDT [SERE]
is_VPRT [BEMA]
likely_PRED
to_TO
reverse_VB
in_PIN
the_DT
future_NN
as_IN
these_DEMO
compounds_NN
reach_VPRT
Share-based_JJ
Payment_NOMZ
,_,
both_DT
of_PIN
which_WDT [PIRE]
came_VBD
into_PIN
force_NN
in_PIN
2005_CD
,_,
regulatory_JJ
approval_NN
and_PHC
amortisation_NOMZ
is_VPRT [SPAU] [PASS]
then_RB
charged_VBN
over_IN
a_DT
shorter_JJ
require_VPRT [SUAV]
the_DT
fair_JJ
value_NN
of_PIN
the_DT
equity_NOMZ
instruments_NOMZ
issued_VBN
to_TO
be_VB
period_NN
._.
profit_NN
before_IN
tax_NN
in_PIN
2004_CD
increases_NN
by_PIN
43_CD
million_CD
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
For_PIN
share_NN
awards_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
2003_CD
43_CD
million_CD
and_CC
EPS_NN
by_PIN
0.5_CD
pence_NN
2003_CD
0.5_CD
pence_NN
._.
senior_JJ
executives_NN
,_,
although_CONC
the_DT
calculation_NOMZ
is_VPRT [BEMA]
different_PRED
,_,
the_DT
resultant_JJ
charge_NN
is_VPRT
not_XX0
materially_RB
different_PRED
from_PIN
that_DEMO
under_IN
UK_NN
GAAP_NN
._.
Goodwill_NN
amortisation_NOMZ
The_DT
major_JJ
difference_NN
arises_VPRT
in_PIN
respect_NN
of_PIN
share_NN
options_NOMZ
:_:
of_PIN
the_DT
UK_NN
GAAP_NN
requires_VPRT [SUAV]
goodwill_NN
to_TO
be_VB [PASS]
amortised_VBN
over_IN
its_PIT
estimated_VBN [PRIV]
368_CD
million_CD
adjustment_NOMZ
in_PIN
2003_CD
,_,
some_QUAN
350_CD
million_CD
arises_VPRT
from_PIN
expected_VBN [PRIV]
useful_JJ
life_NN
,_,
which_WDT [SERE]
GlaxoSmithKline_NN
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
the_DT
grant_NN
of_PIN
share_NN
options_NOMZ
at_PIN
market_NN
price_NN
to_TO
approximately_RB
to_TO
be_VB
normally_RB
no_SYNE
longer_JJ
than_PIN
20_CD
years_NN
._.
GlaxoSmithKline_NN
has_VPRT [PEAS]
chosen_VBN
to_TO
recognize_VB [PRIV] [THATD]
all_QUAN
goodwill_NN
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
have_VB
an_DT
indefinite_JJ
life_NN
and_CC
so_RB
is_VPRT [BEMA]
not_XX0
unvested_JJ
options_NOMZ
and_PHC
awards_NN
retrospectively_RB
._.
amortised_JJ
,_,
but_CC
is_VPRT [BEMA]
subject_PRED
to_PIN
annual_JJ
impairment_NOMZ
testing_GER
._.
This_DEMO
adjustment_NOMZ
therefore_CONJ
reverses_VPRT
the_DT
goodwill_NN
amortisation_NOMZ
charged_VBD
GlaxoSmithKline_NN
receives_VPRT
a_DT
tax_NN
credit_NN
,_,
as_IN
appropriate_JJ
,_,
which_WDT [SERE]
relates_VPRT
under_IN
UK_NN
GAAP_NN
,_,
including_VBG
that_DEMP
recorded_VBN
in_PIN
the_DT
profit_NN
on_PIN
share_NN
to_TO
share_VB
options_NOMZ
and_PHC
awards_NN
when_RB
exercised_VBN
,_,
based_VBN [PASTP]
on_PIN
the_DT
gains_NN
of_PIN
associates_NN
line_NN
relating_VBG [WZPRES]
to_PIN
the_DT
acquisition_NOMZ
of_PIN
the_DT
Groups_NN
interest_NN
the_DT
holders_NN
make_VPRT
and_PHC
dependant_VPRT
on_PIN
the_DT
tax_NN
rules_NN
in_PIN
the_DT
country_NN
in_PIN
Quest_NN
Diagnostics_NN
Inc._NN
._.
Under_IN
the_DT
business_NOMZ
combinations_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
deduction_NOMZ
is_VPRT [PASS]
claimed_VBN [PUBV]
._.
The_DT
deferred_JJ
tax_NN
asset_NN
exemption_NOMZ
of_PIN
IFRS_NN
1_CD
,_,
goodwill_NN
previously_TIME
written_VBN [PUBV]
off_PIN
direct_JJ
to_TO
represents_VPRT
an_DT
estimate_NN
of_PIN
future_JJ
tax_NN
relief_NN
for_PIN
this_DEMO
gain_NN
and_CC
is_VPRT
reserves_NN
under_IN
UK_NN
GAAP_NN
is_VPRT [PASS]
not_XX0
recycled_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
potential_JJ
gains_NN
available_JJ
to_PIN
the_DT
option_NOMZ
or_CC
award_NN
on_PIN
the_DT
disposal_NN
or_CC
part-disposal_NN
of_PIN
the_DT
subsidiary_NN
or_CC
associate_NN
,_,
holders_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
movement_NOMZ
in_PIN
deferred_VBN
as_IN
it_PIT
would_PRMD
be_VB
under_IN
UK_NN
GAAP_NN
._.
The_DT
adjustment_NOMZ
increases_VPRT
2004_CD
tax_NN
asset_NN
from_PIN
one_CD
balance_NN
sheet_NN
to_PIN
the_DT
next_JJ
may_POMD
result_VB
in_PIN
either_CC
a_DT
profit_NN
before_IN
tax_NN
by_PIN
38_CD
million_CD
2003_CD
26_CD
million_CD
and_CC
EPS_NN
by_PIN
tax_NN
credit_NN
or_CC
a_DT
tax_NN
charge_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
This_DEMO
adjustment_NOMZ
reduces_VPRT
profit_NN
before_IN
tax_NN
in_PIN
2004_CD
by_PIN
309_CD
million_CD
2003_CD
368_CD
million_CD
,_,
earnings_GER
by_PIN
314_CD
million_CD
2003_CD
344_CD
million_CD
and_CC
EPS_NN
by_PIN
5.5_CD
pence_NN
2003_CD
5.9_CD
pence_NN
._.
168_CD
GlaxoSmithKline_NN
Financial_NN
information_NOMZ
under_IN
IFRS_NN
IFRS_NN
adjustments_NOMZ
continued_VBD
Deferred_JJ
tax_NN
on_PIN
intercompany_NN
profit_NN
Under_IN
UK_NN
GAAP_NN
,_,
deferred_VBN
tax_NN
on_PIN
the_DT
provision_NN
for_PIN
intercompany_NN
Pensions_NN
and_CC
other_JJ
post-employment_NOMZ
benets_NN
profit_NN
held_VBN [PRIV] [WZPAST]
in_PIN
inventory_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
at_PIN
the_DT
supplying_VBG
companys_NN
GlaxoSmithKline_NN
accounts_VPRT
under_IN
UK_NN
GAAP_NN
for_PIN
pensions_NN
and_CC
other_JJ
effective_JJ
tax_NN
rate_NN
._.
IFRS_NN
,_,
however_CONJ
,_,
takes_VPRT
a_DT
balance_NN
sheet_NN
approach_NN
post-employment_NOMZ
benets_NN
OPEBs_NN
in_PIN
accordance_NN
with_PIN
SSAP_NN
24_CD
,_,
to_PIN
the_DT
recognition_NOMZ
of_PIN
deferred_JJ
tax_NN
which_WDT [WHOBJ]
results_NN
in_PIN
the_DT
tax_NN
rate_NN
of_PIN
which_WDT [PIRE]
spreads_VPRT
the_DT
costs_NN
of_PIN
providing_VBG
the_DT
benets_NN
over_IN
the_DT
the_DT
company_NN
holding_VBG [PRIV] [WZPRES]
the_DT
inventory_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
estimated_VBN [PRIV]
average_JJ
service_NN
lives_NN
of_PIN
the_DT
employees_NN
._.
The_DT
additional_JJ
being_VBG [PASS]
applied_VBN
to_PIN
the_DT
provision_NN
._.
If_COND
the_DT
proportions_NOMZ
of_PIN
the_DT
Groups_NN
FRS_NN
17_CD
disclosures_NN
give_VPRT
the_DT
pension_NN
fund_NN
surpluses_NN
and_PHC
deficits_NN
inventory_NN
held_VBN [PRIV] [WZPAST]
in_PIN
specic_JJ
locations_NOMZ
change_VPRT
signicantly_RB
from_PIN
one_CD
and_CC
the_DT
liabilities_NOMZ
for_PIN
OPEBs_NN
based_VBN [WZPAST]
on_PIN
the_DT
valuation_NOMZ
methodologies_NN
balance_NN
sheet_NN
date_NN
to_PIN
the_DT
next_JJ
there_EX
could_POMD
be_VB
a_DT
significant_JJ
change_NN
required_VBN [SUAV] [WZPAST]
by_PIN
that_DEMO
Standard_NN
._.
in_PIN
the_DT
value_NN
of_PIN
the_DT
deferred_JJ
tax_NN
asset_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
reected_VBN
through_PIN
IAS_NN
19_CD
,_,
Employee_NN
Benets_NN
,_,
takes_VPRT
a_DT
similar_JJ
valuation_NOMZ
approach_NN
to_PIN
the_DT
tax_NN
charge_NN
for_PIN
the_DT
year_NN
._.
FRS_NN
17_CD
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
transitional_JJ
provisions_NN
of_PIN
IFRS_NN
1_CD
the_DT
surpluses_NN
and_PHC
deficits_NN
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
on_PIN
the_DT
balance_NN
Other_JJ
adjustments_NOMZ
sheet_NN
at_PIN
the_DT
transition_NOMZ
date_NN
of_PIN
1st_CD
January_NN
2003_CD
._.
In_CONJ
addition_NULL
,_,
There_EX
are_VPRT
a_DT
number_NN
of_PIN
other_JJ
minor_JJ
adjustments_NOMZ
and_CC
following_VBG
an_DT
amendment_NOMZ
to_PIN
IAS_NN
19_CD
issued_VBN
by_PIN
the_DT
IASB_NN
in_PIN
December_NN
reclassications_NOMZ
,_,
including_VBG
:_:
2004_CD
,_,
it_PIT
is_VPRT [PASS]
permitted_VBN
to_TO
recognize_VB [PRIV]
any_QUAN
movements_NOMZ
in_PIN
the_DT
surpluses_NN
Computer_NN
software_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
recorded_VBN
as_IN
an_DT
intangible_JJ
asset_NN
or_CC
deficits_NN
immediately_TIME
in_PIN
balance_NN
sheets_NN
,_,
but_CC
outside_PLACE
the_DT
income_NN
unless_COND
it_PIT
forms_VPRT
an_DT
integral_JJ
part_NN
of_PIN
the_DT
operating_GER
system_NN
of_PIN
a_DT
statement_NOMZ
,_,
in_PIN
a_DT
similar_JJ
way_NN
to_PIN
FRS_NN
17_CD
._.
This_DEMP
means_VPRT [PRIV] [THATD]
that_DEMP
,_,
in_PIN
most_EMPH
tangible_JJ
xed_JJ
asset_NN
cases_NN
,_,
the_DT
balance_NN
sheet_NN
reects_VPRT
the_DT
full_JJ
surplus_NN
or_CC
deficit_NN
positions_NOMZ
Deferred_VBN
tax_NN
on_PIN
brands_NN
acquired_VBN [WZPAST]
with_PIN
a_DT
company_NN
,_,
where_RB
if_COND
of_PIN
the_DT
funds_NN
._.
there_EX
is_VPRT
a_DT
difference_NN
between_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
brands_NN
on_PIN
The_DT
Groups_NN
policy_NN
is_VPRT
to_TO
charge_VB
out_PIN
to_PIN
the_DT
operating_GER
businesses_NOMZ
acquisition_NOMZ
and_CC
the_DT
tax_NN
value_NN
,_,
a_DT
taxable_JJ
temporary_JJ
difference_NN
the_DT
service_NN
cost_NN
element_NOMZ
of_PIN
the_DT
pension_NN
charge_NN
,_,
which_WDT [SERE]
then_RB
gets_VPRT
arises_VPRT
reported_VBN [PUBV]
within_PIN
cost_NN
of_PIN
sales_NN
,_,
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
Cash_NN
equivalents_NN
reclassication_NOMZ
,_,
where_RB
liquid_JJ
investments_NOMZ
expenditure_NN
or_CC
research_NN
and_PHC
development_NOMZ
as_IN
appropriate_JJ
,_,
but_CC
not_XX0
with_PIN
maturities_NOMZ
of_PIN
less_JJ
than_PIN
three_CD
months_NN
at_PIN
acquisition_NOMZ
are_VPRT
to_TO
charge_VB
out_PIN
the_DT
element_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
funding_GER
deficit_NN
,_,
which_WDT [SERE]
included_VBD
within_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
,_,
and_ANDC
is_VPRT [BEMA]
all_QUAN
reported_VBN [PUBV]
in_PIN
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenditure_NN
._.
Provisions_NN
reclassication_NOMZ
,_,
where_RB
the_DT
elements_NOMZ
of_PIN
provisions_NN
Under_IN
IAS_NN
19_CD
,_,
the_DT
service_NN
cost_NN
element_NOMZ
of_PIN
the_DT
total_JJ
charge_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
within_PIN
one_CD
year_NN
of_PIN
the_DT
balance_NN
sheet_NN
date_NN
,_,
considerably_RB
higher_JJ
than_PIN
under_IN
SSAP_NN
24_CD
and_CC
the_DT
funding_GER
deficit_NN
with_PIN
the_DT
exception_NOMZ
of_PIN
pensions_NN
and_PHC
OPEBs_NN
,_,
are_VPRT [PASS]
presented_VBN
element_NOMZ
lower_JJ
._.
This_DEMP
leads_VPRT
to_PIN
an_DT
additional_JJ
reclassication_NOMZ
within_PIN
current_JJ
liabilities_NOMZ
._.
adjustment_NOMZ
between_PIN
the_DT
income_NN
statement_NOMZ
expense_NN
headings_GER
._.
Cash_NN
ow_NN
statement_NOMZ
In_PIN
the_DT
USA_NN
,_,
the_DT
recently_TIME
enacted_VBN
Medicare_NN
Prescription_NOMZ
Drug_NN
,_,
The_DT
move_NN
from_PIN
UK_NN
GAAP_NN
to_PIN
IFRS_NN
does_VPRT
not_XX0
change_VB
any_QUAN
of_PIN
the_DT
cash_NN
Improvement_NOMZ
and_PHC
Modernization_NOMZ
Act_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
lead_VB
to_PIN
ows_NN
of_PIN
the_DT
Group_NN
._.
The_DT
IFRS_NN
cash_NN
ow_NN
format_NN
is_VPRT [BEMA]
similar_PRED
to_PIN
UK_NN
payments_NOMZ
being_VBG [WZPRES] [BYPA]
received_VBN
by_PIN
GlaxoSmithKline_NN
from_PIN
the_DT
US_FPP1
GAAP_NN
but_CC
presents_VPRT
various_JJ
cash_NN
ows_NN
in_PIN
different_JJ
categories_NN
and_PHC
Government_NOMZ
in_PIN
respect_NN
of_PIN
its_PIT
employee_NN
healthcare_NN
plans_NN
._.
At_PIN
in_PIN
a_DT
different_JJ
order_NN
from_PIN
the_DT
UK_NN
GAAP_NN
cash_NN
ow_NN
statement_NOMZ
._.
All_QUAN
present_JJ
there_EX
is_VPRT
no_SYNE
clear_JJ
consensus_NN
on_PIN
how_RB
these_DEMO
receipts_NN
should_NEMD
of_PIN
the_DT
IFRS_NN
accounting_GER
adjustments_NOMZ
net_JJ
out_PIN
within_PIN
cash_NN
generated_VBD
be_VB [PASS]
accounted_VBN
for_PIN
under_IN
IAS_NN
19_CD
._.
GlaxoSmithKline_NN
has_VPRT [PEAS]
recognized_VBN [PRIV]
from_PIN
operations_NOMZ
except_PIN
for_PIN
the_DT
intangible_JJ
assets_NN
reclassication_NOMZ
these_DEMO
receipts_NN
as_IN
actuarial_JJ
adjustments_NOMZ
and_CC
so_IN
the_DT
impact_NN
of_PIN
them_TPP3
and_CC
the_DT
inclusion_NN
of_PIN
liquid_JJ
investments_NOMZ
with_PIN
a_DT
maturity_NOMZ
of_PIN
less_JJ
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
balance_NN
sheet_NN
._.
This_DEMO
treatment_NOMZ
would_PRMD
change_VB
if_COND
than_PIN
three_CD
months_NN
on_PIN
acquisition_NOMZ
,_,
together_RB
with_PIN
related_JJ
exchange_NN
guidance_NN
is_VPRT [PASS]
issued_VBN
which_WDT
requires_VPRT [SUAV]
a_DT
different_JJ
accounting_GER
treatment_NOMZ
._.
adjustments_NOMZ
,_,
within_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
under_IN
IFRS_NN
._.
The_DT
overall_JJ
impact_NN
of_PIN
the_DT
adjustments_NOMZ
to_PIN
pensions_NN
and_PHC
OPEBs_NN
in_PIN
2004_CD
is_VPRT [BEMA]
a_DT
decrease_NN
in_PIN
profit_NN
before_IN
tax_NN
of_PIN
36_CD
million_CD
2003_CD
increase_NN
of_PIN
11_CD
million_CD
and_CC
a_DT
decrease_NN
in_PIN
EPS_NN
of_PIN
0.4_CD
pence_NN
2003_CD
nil_NN
._.
Share_NN
of_PIN
profits_NN
of_PIN
associates_NN
Under_IN
UK_NN
GAAP_NN
the_DT
share_NN
of_PIN
profits_NN
of_PIN
associates_NN
is_VPRT [PASS]
reported_VBN [PUBV]
within_PIN
profit_NN
before_IN
tax_NN
for_PIN
the_DT
Group_NN
._.
However_CONJ
,_,
IFRS_NN
requires_VPRT [SUAV]
this_DEMO
share_NN
of_PIN
profits_NN
to_TO
be_VB [BEMA]
the_DT
net_JJ
profit_NN
attributable_JJ
to_PIN
the_DT
Group_NN
,_,
i._FW
e._FW
after_IN
interest_NN
,_,
tax_NN
and_PHC
minority_NOMZ
interests_NN
of_PIN
the_DT
associate_NN
._.
This_DEMP
leads_VPRT
to_PIN
a_DT
reclassication_NOMZ
adjustment_NOMZ
removing_VBG [WZPRES]
the_DT
share_NN
of_PIN
the_DT
associates_NN
interest_NN
,_,
tax_NN
and_PHC
minority_NOMZ
interests_NN
from_PIN
those_DEMO
lines_NN
in_PIN
the_DT
income_NN
statement_NOMZ
and_CC
netting_VBG
them_TPP3
all_QUAN
together_RB
in_PIN
the_DT
share_NN
of_PIN
profits_NN
of_PIN
associates_NN
line_NN
._.
This_DEMO
adjustment_NOMZ
reduces_VPRT
2004_CD
profit_NN
before_IN
tax_NN
by_PIN
42_CD
million_CD
2003_CD
42_CD
million_CD
but_CC
does_VPRT
not_XX0
affect_VB
EPS_NN
._.
